Delving into the Latest Updates on Metyrapone/Oxazepam with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

Mechanism

CYP11B1 inhibitors(Steroid 11-beta-hydroxylase inhibitors), GABAA receptor positive allosteric modulators(Gamma-aminobutyric acid A receptor positive allosteric modulators)

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Originator Organization

Louisiana State University

Active Organization-

Inactive Organization

Embera NeuroTherapeutics, Inc.

Rose Research Center LLCStartup

Drug Highest PhasePendingPhase 2/3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC15H11ClN2O2

InChIKeyADIMAYPTOBDMTL-UHFFFAOYSA-N

CAS Registry604-75-1

View All Structures (2)

EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only).
This is an open-label study in up to 50 adult subjects to help smokers abstain from smoking during a 12-week trial period.

Start Date10 Jun 2021

Sponsor / Collaborator

Embera NeuroTherapeutics, Inc.

[+2]

NCT04868253

/ Unknown statusPhase 2/3

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

This open-label study will evaluate EMB-001, comprised of metyrapone, a cortisol synthesis inhibitor marketed as a diagnostic drug for testing hypothalamic-pituitary-adrenal (HPA) axis function, combined with oxazepam, an anxiolytic and sedative/hypnotic benzodiazepine, to help smokers abstain from smoking during a 12-week trial period.

Start Date19 May 2021

Sponsor / Collaborator

Rose Research Center LLCStartup

[+1]

NCT04501874

/ CompletedPhase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of EMB 001 in Subjects With Moderate-to-Severe Cocaine Use Disorder

EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only).
This is a Phase 2 study in approximately 80 adult subjects with moderate-to-severe Cocaine Use Disorder (CUD).

Start Date29 Jul 2020

Sponsor / Collaborator

Embera NeuroTherapeutics, Inc.

[+1]

100 Clinical Results associated with Metyrapone/Oxazepam

Login to view more data

100 Translational Medicine associated with Metyrapone/Oxazepam

Login to view more data

100 Patents (Medical) associated with Metyrapone/Oxazepam

Login to view more data

3

Literatures (Medical) associated with Metyrapone/Oxazepam

14 Feb 2016·Advances in Bioinformatics

Inhibition of Mycobacterium-RmlA by Molecular Modeling, Dynamics Simulation, and Docking

Article

Author: Anuradha, C. M. ; Harathi, N. ; Kumar Chitta, Suresh ; Pulaganti, Madhusudana

The increasing resistance to anti-tb drugs has enforced strategies for finding new drug targets againstMycobacterium tuberculosis(Mtb). In recent years enzymes associated with the rhamnose pathway in Mtb have attracted attention as drug targets. The present work is onα-D-glucose-1-phosphate thymidylyltransferase (RmlA), the first enzyme involved in the biosynthesis of L-rhamnose, of Mtb cell wall. This study aims to derive a 3D structure of RmlA by using a comparative modeling approach. Structural refinement and energy minimization of the built model have been done with molecular dynamics. The reliability assessment of the built model was carried out with various protein checking tools such as Procheck, Whatif, ProsA, Errat, and Verify 3D. The obtained model investigates the relation between the structure and function. Molecular docking interactions of Mtb-RmlA with modified EMB (ethambutol) ligands and natural substrate have revealed specific key residues Arg13, Lys23, Asn109, and Thr223 which play an important role in ligand binding and selection. Compared to all EMB ligands, EMB-1 has shown better interaction with Mtb-RmlA model. The information thus discussed above will be useful for the rational design of safe and effective inhibitors specific to RmlA enzyme pertaining to the treatment of tuberculosis.

01 Jun 1969·Journal of BacteriologyQ3 · BIOLOGY

Secondary and Tertiary Responses of the Induced Bactericidin from the West Indian Spiny Lobster,Panulirus argus

Q3 · BIOLOGY

Article

Author: Evans, Marjorie L. ; Painter, Barbara ; Evans, E. Edward ; Weinheimer, Peter F. ; Acton, Ronald T.

West Indian spiny lobsters,Panulirus argus, synthesized a hemolymph bactericidin after being injected with killed suspensions of gram-negative bacillus EMB-1 isolated from the normal gut of this lobster. To study differences between the primary response and secondary response, animals were given a primary antigen injection of EMB-1 followed by a second injection of the same antigen 22 to 51 days later. As a rule, secondary bactericidal responses were enhanced over the primary in a manner reminiscent of specific anamnesis in mammalian immunoglobulin synthesis. Immunological memory was also suggested when tertiary responses were compared to secondary and by the persistence of residual titers for many days or weeks without additional antigenic stimulation.

01 Jun 1969·Journal of BacteriologyQ3 · BIOLOGY

Specificity of the Induced Bactericidin of the West Indian Spiny Lobster,Panulirus argus

Q3 · BIOLOGY

Article

Author: Evans, E. Edward ; Acton, Ronald T. ; Weinheimer, Peter F. ; Sawyer, Susan

To investigate the specificity of an inducible hemolymph bactericidin, West Indian spiny lobsters were immunized with a variety of antigens. Bactericidal assays were conducted with strain EMB-1, a gram-negative bacillus isolated from normal lobster intestine. Animals given saline solution with or without 0.3% Formalin exhibited only a slight response similar to sham controls. Injections of type 2 pneumococci or bovine albumin produced slightly higher responses. These were much less pronounced than the homologous response to EMB-1. Formalin exhibited an adjuvant-like effect with EMB-1.

100 Deals associated with Metyrapone/Oxazepam

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Smoking Cessation	Phase 3	US	Rose Research Center LLCStartup	19 May 2021
Smoking Cessation	Phase 3	US	Embera NeuroTherapeutics, Inc.	19 May 2021
Tobacco Use Disorder	Phase 3	US	Rose Research Center LLCStartup	19 May 2021
Tobacco Use Disorder	Phase 3	US	Embera NeuroTherapeutics, Inc.	19 May 2021
Cocaine-Related Disorders	Phase 3	US	Embera NeuroTherapeutics, Inc.	29 Jul 2020